Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Cellectis S.A. ADR (CLLS)

Cellectis S.A. ADR (CLLS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 112,836
  • Shares Outstanding, K 55,584
  • Annual Sales, $ 9,190 K
  • Annual Income, $ -101,060 K
  • 60-Month Beta 3.10
  • Price/Sales 13.06
  • Price/Cash Flow N/A
  • Price/Book 1.33
Trade CLLS with:

Options Overview Details

View History
  • Implied Volatility 83.76% ( -0.76%)
  • Historical Volatility 52.99%
  • IV Percentile 52%
  • IV Rank 32.79%
  • IV High 244.92% on 11/16/23
  • IV Low 5.12% on 03/12/24
  • Put/Call Vol Ratio 0.09
  • Today's Volume 24
  • Volume Avg (30-Day) 34
  • Put/Call OI Ratio 0.75
  • Today's Open Interest 421
  • Open Int (30-Day) 344

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.33
  • Number of Estimates 1
  • High Estimate -0.33
  • Low Estimate -0.33
  • Prior Year -0.14
  • Growth Rate Est. (year over year) -135.71%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.82 +11.54%
on 06/27/24
2.20 -7.73%
on 07/17/24
+0.01 (+0.74%)
since 06/18/24
3-Month
1.82 +11.54%
on 06/27/24
3.38 -39.94%
on 05/06/24
-0.52 (-20.39%)
since 04/19/24
52-Week
0.96 +110.84%
on 10/26/23
3.77 -46.20%
on 12/20/23
-0.24 (-10.57%)
since 07/19/23

Most Recent Stories

More News
There's a Lot of Upside For Emerging Gene-Editing Companies

These four gene-editing companies are brand new, with very high upside potential. The industry itself is still emerging, which means more growth could come.

CRBU : 2.30 (-4.38%)
CLLS : 2.03 (-6.02%)
DTIL : 9.88 (-0.50%)
SGMO : 0.3971 (-1.49%)
Pre-Market Brief: Stocks Mixed As Brutal Year Nears End

March S&P 500 futures (ESH23) are trending down -0.45% this morning after three major U.S. benchmark indices ended the regular session higher, powered by a rebound in mega-cap growth stocks as U.S. unemployment...

ESH23 : 3,957.05s (-0.09%)
META : 476.79 (+0.20%)
AAPL : 224.31 (+0.06%)
SESN : 12.5760 (+7.29%)
HOTH : 0.8222 (-7.68%)
CLLS : 2.03 (-6.02%)
ORIC : 10.22 (unch)
PFE : 29.97 (+0.88%)
TGTX : 21.00 (-1.08%)
Omega Therapeutics Announces Appointment of Rainer Boehm to its Board of Directors

/PRNewswire/ -- Omega Therapeutics, Inc. (Nasdaq: OMGA) ("Omega"), a clinical-stage biotechnology company pioneering the first systematic approach to using...

CLLS : 2.03 (-6.02%)
HGEN : 0.0002 (-84.62%)
OMGA : 1.7900 (-2.72%)
Cellectis Provides Business Update and Reports Financial Results for Second Quarter 2022

  IND clearance received from FDA for UCART20x22 for the treatment of Non-Hodgkin LymphomaCellectis unveiled novel immune-evasive universal allogeneic CAR...

CLLS : 2.03 (-6.02%)
Cellectis Receives IND clearance for UCART20x22, its First in-house Manufactured Product Candidate for the Treatment of B-cell Malignancies

UCART20x22 is Cellectis’ first allogeneic dual CAR T, targeting CD20 and CD22 simultaneously UCART20x22 is Cellectis’ first product candidate fully...

CLLS : 2.03 (-6.02%)
Cellectis to Report Second Quarter 2022 Financial Results

NEW YORK, July 28, 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its...

CLLS : 2.03 (-6.02%)
Cellectis Publishes Article in Nature Communications Unveiling Novel Immune-Evasive Universal Allogeneic CAR T-cells with Potential for Improved Persistence

NEW YORK, June 30, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company...

CLLS : 2.03 (-6.02%)
Cellectis Announces the Appointment of Axel-Sven Malkomes & Dr. Donald A Bergstrom, M.D., Ph.D., to its Board of Directors

NEW YORK, June 28, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company...

CLLS : 2.03 (-6.02%)
Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 28, 2022

NEW YORK, June 28, 2022 (GLOBE NEWSWIRE) -- Cellectis S.A. held its Annual Shareholders’ General Meeting (Euronext Growth: ALCLS – Nasdaq: CLLS) on June...

CLLS : 2.03 (-6.02%)
Monthly information on share capital and company voting rights

(Article 223-16 of General Regulation of the French financial markets authority)...

CLLS : 2.03 (-6.02%)

Business Summary

Cellectis SA is a gene-editing company. The company focused on developing immunotherapies based on gene edited engineered CAR-T cells. Cellectis SA is based in Paris, France.

See More

Key Turning Points

3rd Resistance Point 2.19
2nd Resistance Point 2.16
1st Resistance Point 2.09
Last Price 2.03
1st Support Level 1.99
2nd Support Level 1.96
3rd Support Level 1.89

See More

52-Week High 3.77
Fibonacci 61.8% 2.70
Fibonacci 50% 2.37
Fibonacci 38.2% 2.04
Last Price 2.03
52-Week Low 0.96

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar